Document is current
Any future updates will be listed below
-
Authors
Sas, David J.
Bakkaloglu, Sevcan A.
Belostotsky, Vladimir
Hayes, Wesley
Ariceta, Gema
Zhou, Jing
Rawson, Verity
- License Information
-
More Information
Article History
Received: 24 September 2024
Revised: 6 December 2024
Accepted: 5 January 2025
First Online: 28 January 2025
Declarations
:
: The PHYOX8 study was approved by the (local) IRB: Dubai Scientific Research Ethics Committee (DSREC; United Arab Emirates—DSREC-01/2023_07); Hamilton Integrated Research Ethics Board (Canada—REB-ProID_13895); Heidelburg University Ethics Committee of the Med. Faculty (Germany—AFmu-511/2021); Hospital Germans Trias i Pujol (Spain—AC-21–081-EXT-CEIM); South Central—Hampshire A Research Ethics Committee (England—21/SC/0222); Ospedale Pediatrico Bambino Gesu (Italy—2550–10/2021); Nagoya City University Institutional Review Board (Japan); Institutional Review Board Kurume University Hospital Clinical Trial Review Board (Japan—no specific approval number); Comité d’éthique Hôtel-Dieu de France (Lebanon—CEHDF 1860); Białystok Medical University (Poland—APK.002.316.2021), Gazi University Medical Faculty Clinical Trials Ethics Committee (Turkey—no specific approval number); Western-Copernicus Group (WCG; United States—21–005579).
: DJS has received research funding from Alnylam and Novo Nordisk and consulting fees from Advicenne Pharmaceuticals. SAB and VB have no conflict of interests. WH has received research funding from the National Institute for Health Research (NIHR) and honoraria from Alnylam. JZ and VR are employees and shareholders of Novo Nordisk. GA is a consultant for and has received honoraria from AstraZeneca Alexion, Recordati, Chiesi, Kyowa Kirin, and Advicenne; is a consultant for Novo Nordisk and Alnylam; and is a scientific advisor for AstraZeneca Alexion.
